Under the new price transparency rule, hospitals will soon be required to publish the price of everything from individual medical supplies to the total cost of common procedures.
The poll found 46% of likely U.S. voters oppose the universal health care plan similar to those proposed by 2020 Democratic candidates like Sens. Bernie Sanders and Elizabeth Warren, while 39% are in favor of such a program, the poll shows.
She continues to claim that this will cost “not one penny in middle-class tax increases.” Even Bernie Sanders called her out on that assertion.
In 2015, Medicaid accounted for 20 percent of state budget spending. According to new research by the Foundation for Government Accountability, Medicaid spending now accounts for 30 percent of state budgets, skyrocketing to an estimated $603 billion in 2018.
Warren’s campaign said her single-payer health plan would cost “just under” $52 trillion over a decade, including $20.5 trillion in new federal spending.
The White House is laying out a “Health Care for You” agenda to boost competition and transparency, lower prescription prices, and produce greater affordability in health-related costs.
When you pay attention to health care reform efforts in Vermont, unfortunately, you’re almost certain to develop neck and spine problems from shaking your head.
We now have a feel for how this massive government intrusion into the health care market is working. It isn’t. It’s time to pull the plug on this program now, before it gets to be “too big to fail.”
The president’s executive order comprises a broad range of reforms and directives that, taken together, have the effect of lightening the burden of government on the practice of health care.
Vermonters have recently witnessed, once again, the annual battle over health insurance rate increases for individual and small business plans. It’s worth taking a long look at just what the state thinks it’s doing, and how it does it.
In Sanders’ signature “Medicare for All” bill, drug prices would be essentially set by the secretary of health and human services. Once Medicare for All empowers the secretary to decide the appropriate revenue for a drug company, what will happen to that $121 billion of research investment?
Average premiums for “benchmark” plans declined slightly (0.83%) in 2019, for the first time in the program’s history. The better news is that this overall decline was driven by seven states that obtained waivers to deviate from certain Obamacare mandates.